Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Retatrutide

LY3437943, LY-3437943

Quick Stats
Studies 83
Trials 32
Score 4
2024 pubmed 73 citations

Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?

Locatelli. João Carlos JC; Costa. Juliene Gonçalves JG; Haynes. Andrew A; Naylor. Louise H LH; Fegan. P Gerry PG; Yeap. Bu B BB; Green. Daniel J DJ

Key Findings

  • Incretin‑based drugs (GLP‑1, GIP, glucagon agonists) produce large fat loss but also rapid lean‑mass loss comparable to years of aging.
  • Supervised resistance exercise for >10 weeks can increase lean mass by ~3 kg and strength by ~25% in both men and women.
  • Combining aerobic exercise with liraglutide after a low‑calorie diet improves weight‑loss maintenance versus either strategy alone.

Practical Outcomes

  • If you’re using retatrutide or similar peptides for weight loss, schedule regular resistance‑training sessions (e.g., 3‑4 times per week, focusing on progressive overload) for at least 10 weeks to protect muscle. Pair this with adequate protein intake (≈1.6‑2.2 g/kg body weight) and consider adding aerobic work for overall health and better weight‑maintenance after stopping the drug.

Summary

New weight‑loss peptides like retatrutide can help you drop 15‑24% of body weight, but they also cause a noticeable loss of muscle (about 10% or 6 kg). Adding a structured resistance‑training program (at least 10 weeks long) can add back roughly 3 kg of lean mass and boost strength by ~25%, helping you keep the muscle you lose while still burning fat.

Abstract

This narrative review highlights the degree to which new antiobesity medications based on gut-derived nutrient-stimulated hormones (incretins) cause loss of lean mass, and the importance of resistance exercise to preserve muscle. Glucagon-like peptide 1 receptor agonists (GLP-1RA) induce substantial weight loss in randomized trials, effects that may be enhanced in combination with glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. Liraglutide and semaglutide (GLP-1RA), tirzepatide (GLP-1 and GIP receptor dual agonist), and retatrutide (GLP-1, GIP, and glucagon receptor triple agonist) are peptides with incretin agonist activity that induce ∼15-24% weight loss in adults with overweight and obesity, alongside beneficial impacts on blood pressure, cholesterol, blood glucose, and insulin. However, these agents also cause rapid and significant loss of lean mass (∼10% or ∼6 kg), comparable to a decade or more of aging. Maintaining muscle mass and function as humans age is crucial to avoiding sarcopenia and frailty, which are strongly linked to morbidity and mortality. Studies indicate that supervised resistance exercise training interventions with a duration >10 weeks can elicit large increases in lean mass (∼3 kg) and strength (∼25%) in men and women. After a low-calorie diet, combining aerobic exercise with liraglutide improved weight loss maintenance compared with either alone. Retaining lean mass during incretin therapy could blunt body weight (and fat) regain on cessation of weight loss pharmacotherapy. We propose that tailored resistance exercise training be recommended as an adjunct to incretin therapy to optimize changes in body composition by preserving lean mass while achieving fat loss.

Study Information

Provider

pubmed

Year

2024

Date

2024-10-01T00:00:00.000Z

DOI

10.2337/dci23-0100

Citations

73